Objectives: To elucidate the signal transduction pathway, by which cyclooxygenase-2 (COX-2) regulates human erg-related gene (HERG) current in gastric cancer cells. Methods: The HERG mRNA, protein and current in gastric cancer cells transfected with or without COX-2 antisense vector were measured by RT-PCR, Western blot and patch-clamp, respectively. Cyclic adenosine monophosphate (cAMP) concentration in gastric cancer cells transfected with or without COX-2 antisense vector was measured by ELISA. Results: Transfection with COX-2 antisense vector did not alter the expression of HERG mRNA and protein, but it diminished the amplitude of HERG current in gastric cancer cells (p < 0.05). The cAMP concentration in gastric cancer cells transfected with COX-2 antisense vector was lower than that in parental gastric cancer cells (p < 0.05). COX-2 inhibitor and PGE2 had infl uence on the HERG current in gastric cancer cells. COX-2 inhibitor reduced the amplitude of HERG current in gastric cancer cells and PGE2 enhanced the amplitude. However, in gastric cancer cells transfected with HERG mutant deleting cAMP-binding domain, both COX-2 inhibitor and PGE2 did not show signifi cant effects on HERG current. cAMP agonist enhanced the amplitude of HERG current and cAMP antagonist reduced the amplitude in gastric cancer cells. Both agonist and antagonist of cAMP had no signifi cant effect on HERG current in gastric cancer cells transfected with HERG mutant deleting cAMP binding domain. PKA inhibitor did not infl uence the HERG current whether in parental gastric cancer cells or in gastric cancer cells transfected with HERG mutant. Conclusions: COX-2 regulates HERG current through its catalytic product PGE2, which alters cAMP level in gastric cancer cells. cAMP interacts with HERG protein by binding with cAMP-binding domain of HERG protein and exerts impact on HERG current. PKA does not participate in this process (Tab. 1, Fig. 2, Ref. 18). Text in PDF www.elis.sk.
COX-2 plays an important role in carcinogenesis of several cancers, including colon cancer and gastric cancer. Some studies showed COX-2 was associated with the development of gastric cancer (1, 2) but its mechanism is still unclear. Our previous studies showed that COX-2 could affect the delayed rectifying potassium current in gastric cancer cells (3, 4) and the expression of αsubunit of delayed rectifying potassium channel (HERG protein) was associated with biological behaviour of gastric cancer cells (5, 6) . Based on the analysis of the structure of HERG protein and COX-2 related signal pathways, we designed the present study to explore the mechanism by which COX-2 regulates HERG current in gastric cancer cells.
Materials and methods

Chemicals and reagents
Celecoxib (Cearal; PGE2 (Sigma); 8-bromo-cAMP (Sigma); Rp-cAMP (Biolog Life Science); PKI (Sigma); LipofectmineTM 2000 (Invitrogen); T4 DNA ligase and restriction endonucleases (Takara Bio Co, Ltd.).
Cell culture
The human gastric cancer SGC7901 cell line, SGC7901 cell line transfected with COX-2 antisense vector (SGC7901-c, constructed by Han-Ping Wu) and human immortalized gastric epithelial GES cell line were cultured in RPMI1640 medium containing 10 % heat-inactivated fetal bovine serum and incubated at 37 °C in a humidifi ed atmosphere with 5 % CO 2 .
RT-PCR
Total RNA from subconfl uent cultures of gastric cancer cells was isolated using Catrimox-14 RNA isolation kit (Takara Bio Co, Ltd.). RNA purity and integrity was checked by running an aliquot on a 1 % agarose gel. 1-2 μg were reverse transcribed in a 20 μl reation by AMV Rtase (Takara Bio Co, Ltd.) 10U, 5×buffer 4 μl, dNTPs (ea.10 mM) 2 μl, RNAse Inhibitor 20 U and Oligo (dT)18 50 pmol, for 1 h at 42 °C. 5 μl of cDNA were amplifi ed by the polymerase chain reaction in a 50 μl reaction containing Takara Taq polymerase 5 U μl -1 (Takara Bio Co, Ltd.), 2.5 mM MgCl 2 , 200 μM d(NTP)s, 1×PCR buffer. The sequence of primers was as follows:
primer sense: 5'-TCCAGCGGCTGTACTCGGGC-3' primer antisense: 5'-TGGACCAGAAGTGGTCGGAGA-ACTC-3'.
These primers comprise a sequence between nucleotide 2171 to nucleotide 2746 of the HERG sequence (accession number HU04270). PCR was performed as follows: 43 cycles (94 °C, 90s; 65 °C, 180s; 72 °C, 90 s), followed by a fi nal extension for 10 min at 72 °C. β-actin served as an internal control. Products were run on a 1 % agarose gel and bands were visualized by ethidium bromide staining on a UV transilluminator.
Western blot
Cell proteins were separated by SDS polyacrylamide gel electrophoresis and transferred to a nitrocellulose sheet. After transfer, the membranes were blocked for 4 h at room temperature with TBST containing 5 % BSA and then incubated overnight at 4 °C with anti-HERG polyclonal antibody (Santa Cruz Bio) diluted 1:1000 in TBST. Membranes were then washed 3 times with TBST and incubated with anti-goat peroxidase-conjugate secondary antibodies for 1 h at room temperature. After 3 washes with TBST, the immunoreactivity was determined by a chemiluminescent reation. β-actin served as an internal control.
Patch-clamp recordings
Patch-clamp recordings were performed at room temperature with an amplifi er Axonpatch 1-D (Axon Instruments). The whole cell confi guration of the patch-clamp technique was employed, using pipettes whose resistance was in the range of 3-5MΩ. Extracellular solutions were delivered through a remote-controlled linear positioner placed near the cell under study. The extracellular solution contained (mM): NaCl 95, KCl 40, CaCl 2 2, Hepes 10, glucose 5, pH 7.4. The standard pipette solution contained (mM): KCl 130, NaCl 10, MgCl 2 2, CaCl 2 2, EGTA 10, Hepes 10, pH 7.4. Gigaseal resistance was in the range of 3-20 GΩ. Whole cell currents were fi ltered at 5 kHz. Input resistance of the cells was in the range of 2-6 GΩ.
Measurement of cAMP concentration
cAMP concentration in gastric cancer cells transfected with or without COX-2 antisense vector was measured by ELISA according to the instructions of the kit (B&D, No DE0450). Total Activity (TA), Non-Specifi c Binding (NSB), Maximum Binding (B0), and Substrate Blank wells were run as a means of quality control for each assay.
Briefl y, the culture media was removed by aspirating or decanting. The cells were lysed by adding 0.1 M HCl. After incubation for 10 minutes, the cells were centrifuged at 600 x g and the supernate was collected. Fiftyμl of cell supernates were added into 200 μl Assay Buffer ED2. One hundred and fi fty μl of Assay Buffer were added into the NSB wells. One hundred μl of Assay Buffer were added into B0 wells and 100μl of Standard or sample were added into the remaining cells. Fifty μl of cAMP conjugate were added into each well (excluding the TA and Substrate Blank wells). Fifty μl of cAMP Antibody Solution were added into each well (excluding the NSB, TA and Substrate Blank wells), followed by incubation for 2 hours at room temperature on a horizontal orbital microplate shaker set at 500 rpm. Each well was aspirated and washed, repeating the process twice for a total of three washes. Five μl of cAMP conjugate into the TA wells. Two hundred μl of pNPP substrate were added into all wells, followed by incubation for 1 hour at room temperature on the benchtop. Fifty μl of Stop Solution were added into each well. The optical density of each well was immediately determined using a microplate reader set to 405 nm with wavelength correction set between 570 nm and 590 nm. The concentration of cAMP corresponding to the mean absorbance was calculated from the standard curve, which was generated according to the instructions of the kit.
Construction of HERG mutant without cAMP-binding domain
Primers:
The template was pcDNA3.0-HERG provided by Prof. Gail Robertson from Wisconsin-Madison University. Briefl y, the product I and II of PCR were obtained using primers F1/MR and SP6/ MF, respectively. Then the product I and II were mixed as template and product III was produced using primers F1/SP6. Product III was digested by XhoI restriction enzyme and purifi ed as insert DNA. pcDNA3.0-HERG was digested by XhoI and the purifi ed 7.0kb segment was referred as vector DNA. Insert DNA and vector DNA were ligated using T4 DNA ligase and the recombinant was transformed into competent cells. Ampicillin-resistant colonies were chosen, identifi ed by PCR using primers F1/M, and further confi rmed by DNA sequencing.
Transfection
SGC7901 cells were planted into six-well plates and cultured in drug-free medium. At 90-95 % confl uence, cells were washed twice with PBS and grown in 2ml DMEM without antibiotics. Using Lipofectamine 2000 reagent, two μg of plasmids were transfected into SGC7901cells according to the manufacturer's instructions. Forty-eight hours later, cells were placed in growth medium containing G418 (GIBCO) for clone selection. The positive clones were named as SGC7901Δ cell line.
The effects of different agents on HERG current in SGC7901 and SGC7901Δ cell line
The SGC7901 and SGC7901Δ cells were treated with Celecoxib (320 μM), PGE2 (100 μM), 8-bromo-cAMP (500 μM) and Rp-cAMP (100 μM) for 5 minutes, respectively. Then the HERG currents in the treated and control gastric cancer cells were mea-sured using patch clamp. The SGC7901 and SGC7901Δ cells pretreated with PKI (1 μM) for 5 minutes were treated with or without PGE2 (100 μM) and the HERG currents in these cells were recorded.
Statistical analysis
Results are expressed as mean ± standard deviation (SD). Statistical analyses were performed with SPSS 11.0 statistical software. Independent-Samples t-test was adopted. Signifi cance was defi ned as p < 0.05.
Results
The effects of COX-2 on HERG mRNA, protein and current in gastric cancer cells
As shown in Figures 1 and 2 , there was no difference in the expression of HERG mRNA and protein between SGC7901 and SGC7901-c cells, indicating that COX-2 does not infl uence the transcription and translation of HERG gene in gastric cancer cells. But the amplitude of HERG current in SGC7901-c (63.2133 ± 1.85648pA) was lower than that in SGC7901 (82.6833 ± 1.58863pA) (p < 0.05, n = 3).
The effect of COX-2 on cAMP concentration in gastric cancer cells
The cAMP concetration in SGC7901-c cells (1.4533 ± 0.41986pM) was signifi cantly lower than that in SGC7901 cells (3.0167 ± 0.78002pM) (p < 0.05, n = 3).
The construction of mutant HERG-ΔNBD
Electrophoresis showed that PCR product I, II and III presented with anticipated molecular weight. The mutant with proper insert was verifi ed by PCR using primers F1/MR and confi rmed by DNA sequencing. The deleted DNA sequence was 5'-CCT GGC AAG TCG AAC GGG GAT GTG CGG GCC CTC ACC-3', whose translation product would be PGKSNGDVRALT, which is the cAMP binding domain. The mutant was named as HERG-ΔNBD.
The effects of COX-2 inhibitor and signal molecules on HERG current in SGC7901 and SGC7901-Δ
As shown in Table 1 , COX-2 inhibitor reduced the amplitude of HERG current and PGE2 enhanced the amplitude in SGC7901 cells. However, in SGC7901-Δ cells both, COX-2 inhibitor and PGE2 did not show signifi cant effects on HERG current. cAMP agonist enhanced the amplitude of HERG current and cAMP antagonist reduced the amplitude in SGC7901 cells. Both agonist and antagonist of cAMP had no signifi cant effect on HERG current in SGC7901-Δ cells. PKA inhibitor did not infl uence the HERG current whether in SGC7901 cells or in SGC7901-Δ cells.
Discussion
Our results showed that COX-2 did not affect the expression of HERG protein in gastric cancer cells but COX-2 did infl uence the HERG current in gastric cancer cells, indicating the regulation takes place after translation process. ELISA assay showed COX-2 increased the cAMP concentration in gastric cancer cells. Wu et al reported that COX-2 could increase the activity of PKA in gastric cancer cells, but the total amount of PKA was not changed (3) . By deleting the cAMP binding domain in HERG protein and detecting the effects of different signal molecules on HERG current, we found that COX-2 could infl uence HERG current through cAMP without PKA involving.
COX enzymes catalyze the synthesis of prostaglandins (PGs) from arachidonic acid. The two isoforms of COX, COX-1 and COX-2, differ in many respects. COX-1 is expressed constitutively in most tissues, but COX-2 is not detected in most normal tissues. COX-2 is induced by mitogenic and infl ammatory stimuli. Epidemiological studies showed that the use of non-steroidal anti-infl ammatory drugs (NSAIDs), which inhibits the activity of COX-2, is associated with a reduced risk of several malignancies (7, 8 ited in animals that are either engineered to be COX-2 defi cient or treated with a selective COX-2 inhibitor. There are multiple mechanisms through which COX-2 may play a role in carcinogenesis. A number of these mechanisms are likely to result from COX-2-induced increase in PG synthesis. Increased PG synthesis has both, growth-promoting and positive feedback effects in cancer cells. Some studies provided evidence that increased expression of COX-2/PGE2 contributes to cancer development and progression via activation of the IL-6 signaling pathway. COX-2 over-expression has been shown to up-regulate Bcl-2 expression with an associated decrease in apoptosis. In addition, COX-2 was found to be induced by TNF-α, which underlines the inducibility of COX-2 in response to pro-infl ammatory stimulus. Other effects of COX-2 overexpression that may contribute to the malignant phenotype include decreased E-cadherin expression with consequent loss of cell-to-cell adhesion, matrixmetalloproteinase overexpression with an associated increase in invasiveness, and modulated production of angiogenic factors by cancer cells. Moreover, the COX-2-dependent effect on VEGF up-regulation was found to be inhibited by treatment with COX-2 specifi c inhibitor and this inhibitory effect was reversed by PGE2 treatment. Since VEGF plays an important role in angiogenesis, its up-regulation by COX-2 expression and inhibition by COX-2 specifi c inhibitor suggested a positive role of COX-2 in angiogenesis, an important event in cancer metastasis. Some studies suggested that overexpression of COX-2 in cancer cells places an additional burden on antioxidative defenses of the cell, which might contribute to DNA oxidation and the induction of mutation. Further, studies have also shown that overexpression of COX-2 in cancer cells inhibited immune surveillance and increased metastatic potential.
Our previous studies revealed that COX-2 is overexpressed in most gastric cancer tissues and associated with differentiation of gastric cancer. The overexpression of COX-2 was also found in gastric cancer cells accompanied with high PGs production (1). Inhibiting COX-2 could inhibit proliferation and increase apoptosis of gastric cancer cells (9) . Our results also demonstrated that COX-2 was associated with delayed rectifying potassium current in gastric cancer cells and inhibiting expression or activity of COX-2 could diminish the delayed rectifying potassium current in gastric cancer cells (3, 4) . Until now, there is no published report about the relationship between COX-2 and delayed rectifying potassium current in gastric cancer cells.
Most reports about COX-2 and delayed rectifying potassium channel are confi ned in the fi eld of regulation of vascular tension and neuron. Some studies indicated that catalyzing products of COX-2 may regulate delayed rectifying potassium channel through cAMP. Several reports showed that PGs could activate delayed rectifying potassium channel. For example, in smooth muscle of the guinea-pig coronary artery the slow hyperpolarization is possibly produced by endothelial prostanoids through activation of delayed rectifying potassium channel, which could be blocked by COX-2 inhibitor (10) . A study on presynaptic modulation showed that COX-2 inhibitor could block delayed rectifying potassium channel and exogenous PGE2 could activate the channel implying that PGs positively modulate delayed rectifying potassium currents (11) .
However, other studies showed that PGs inhibited delayed rectifying potassium channel. For example, in sensory neuron delayed rectifying potassium current was inhibited by PGE2 and regulated by PKA (12) . PGs inhibited delayed rectifying potassium channel through PKA in megakaryocyte (13) . These results revealed the different effects of PGs on delayed rectifying potassium channel in specifi c cells and different physiological processes.
The HERG protein contains a putative cyclic nucleotide binding domain (CNBD) in its cytoplasmic carboxyl terminus and four potential PKA phosphorylation sites, which means elevation of cAMP can modulate HERG channel by direct binding or indirect regulation through PKA. Over-expression of COX-2 can lead to cAMP elevations in gastric cancer cells. So we speculate that CNBD domain may play a role in the regulation of HERG current by COX-2 in gastric cancer cells. A previous study showed PKA can infl uence the HERG current (14) . However, the existence of CNBD domain in the carboxyl terminus of HERG protein indicates that cAMP may directly regulate HERG channel independent of PKA. Cui et al measured the HERG current in CHO cells expressing cloned HERG and found decrease in HERG amplitude after introduction of cAMP analog. PKI, the specifi c PKA inhibitor, prevented the cAMP-mediated current reduction. After the four phosphorylation sites for PKA were mutagenized, cAMP can still affect the HERG current mediated by the non-PKA phosphorylatable mutants, indicating that cAMP may regulate the HERG current by dual pathways (15) . Previous studies identifi ed six invariant key amino acid residues for cyclic nucleotide binding. Three of these are glycine residues that are essential for maintenance of the β-barrel structure that is required to form a pocket for cyclic nucleotide binding. A glutamic acid residue forms a hydrogen bond with the ribose 2'-OH of cAMP and an arginine residue interacts with the phosphate of cAMP to form a salt bridge. Mutagenesis of any of these invariant amino acid residues impairs or eliminates cAMP binding. Mutant HERG proteins do not have a dominant-negative effect on wild-type current but do alter voltage-dependent gating. Compared with wild-type HERG homotetramer, co-expression of wild-type with mutant HERG did not signifi cantly alter current amplitude. The mechanism by which CNBD affects HERG current is still unclear. One possibility is that CNBD binding with cAMP leads to the conformational change of HERG protein and then activates the potassium channel. Another possibility is that CNBD interacts with small proteins in cell membrane such as minK and KCNE2, which in turn affect potassium channel (16) . Intracellular elevation of cAMP can regulate HERG current by directly binding to CNBD or indirectly via PKA pathway. Several studies indicated that various stimuli can affect HERG current by increasing intracellular cAMP (17) . A study showed that HERG mutant deleting CNBD domain but preserving carboxyl terminus still can produce HERG current.(18) Based on our results and literature, we concluded that in gastric cancer cells COX-2 regulates HERG current through its catalytic product PGE2, which binds with its receptor on the gastric cancer cells and alters cAMP level in gastric cancer cells. cAMP interacts with HERG protein by binding with cAMP-binding domain of HERG protein and exerts an impact on HERG current. PKA does not participate in this process.
